Pharmosa Biopharm Inc. (TPEX:6875)

Market Cap	3.27B -54.5%
Revenue (ttm)	53.38M -69.3%
Net Income	-351.33M
EPS	-2.72
Shares Out	129.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,739
Open	25.50
Previous Close	26.00
Day's Range	24.70 - 25.60
52-Week Range	24.80 - 58.70
Beta	0.26
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 40
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6875

Financial Performance

In 2025, Pharmosa Biopharm's revenue was 67.27 million, a decrease of -59.86% compared to the previous year's 167.57 million. Losses were -383.85 million, 130.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error